Edison Investment Research - Mineral Commodities Ltd. (MRC) Update: Rising production profile, exploration appeal

Report

Edison Investment Research

Update: Rising production profile, exploration appeal

Mineral Commodities (MRC) plans to complete its Tormin plant optimisation in July 2016. It is expected to increase heavy mineral (HM) recoveries and produce higher-grade, higher value-add products and result in additional production capacity and enhanced operating flexibility. MRC will be able to capitalise on its expanded exploration programme for high-grade resources in the region.

24/06/2016 10 EN

Underlying

Mineral Commodities Ltd.

Mineral Commodities principal activities are mineral sands mining and processing at the Group's Tormin Mineral Sands Project in the Western Cape Province of South Africa, undertaking procedures and evaluation for the future development of the Xolobeni Mineral Sands Project in the Eastern Cape Province of South Africa, and investigations into other mineral resources. Co. has three reportable segments: Mineral Sands mining and production (Tormin Mineral Sands project) – South Africa; Mineral Sands exploration (Xolobeni Mineral Sands project) – South Africa; and Corporate (management and administration of Co.'s projects) – Australia and South Africa.

See profile

AU000000MRC8 Australian Securities Exchange Australia

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

SmartInsider

Mineral Commodities Limited: 1 director maiden bought

A director at Mineral Commodities Limited maiden bought 250,000 shares at 0.327AUD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Free Trial

November 5, 2020 November 5, 2020 1 EN

Ford Equity Research

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stockâ€™s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

EUR 18.48

December 16, 2016 December 16, 2016 2 EN

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol c 220 patients with cognitive impairment (CI) associated with biomarker-positive mild-to-moderate Alzheimer’s disease (AD), as confirmed through an elevated level of phosphorylated Tau-181 (pTau-181) protein in their blood at baseline. The study has commenced at 13 Australian sites and will concentrate on domestic sites for the first c 100 patients, and initial efficacy and safety results will b...

1h / 31m 1h / 31m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subje...

1h / 53m 1h / 53m 1 EN

Pedro Fonseca

Pedro Fonseca

Tetragon Financial Group - FY23 growth driven by idiosyncratic factors

Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return (TR) in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 performance was below the 26.3% return of the S&P 500 Index, which rallied on the artificial intelligence (AI) theme. Tetragon’s FY23 return on equity (RoE) of 5.5% was below its target of 10–15% pa. That said, its performance since listing was within the target range at 11.3%. Tetragon continues payouts to its shareholders, distributing US$83.6m in FY23 through buybacks an...

3h / 3m 3h / 3m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: Rising production profile, exploration appeal

Mineral Commodities Limited: 1 director maiden bought

Ford Equity International Rating and Forecast Report

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Tetragon Financial Group - FY23 growth driven by idiosyncratic factors

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe